
Blood Clotting Therapies At
THE HEART OF HUMAN RESILIENCE.
No Patient With A
Clotting Disorder
LEFT BEHIND.

The First-Ever Preventative Treatments For


*Currently using monovalent and bispecific antibodies, with intention of expanding to other modalities
Preventing The Full Spectrum Of
Leveraging validated advanced technologies and key insights into the biology of clotting, Hemab’s approach is prime for widespread expansion into a range of underserved bleeding and thrombotic disorders, including Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others.

We are committed to finding and serving patients that have been left behind despite recent innovative therapies. Our strategic guidance, Hemab 1-2-5TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.
If you have questions about our ongoing clinical trials, please contact clinicaltrials@hemab.com.
Building The Ultimate
CLOTTING COMPANY.

































Benny Sorensen, MD, PhD CEO

Mads Behrndt, MSc CFO & General Manager

Cécile Bonvoisin, MSc Senior Vice President, CMC and Manufacturing

John Maraganore, PhD Board Chair

Linda Bain Director

Laura Tadvalkar, PhD, MSc Director

Jørgen Søberg Petersen, MD, PhD, DSc, MBA Director

Mårten Steen, MD, PhD Director

Dan Becker, MD, PhD Director
